Tag: Clinical Trials

Longer progression-free survival seen with nivolumab + doxorubicin, vinblastine, and dacarbazine (AVD) versus brentuximab vedotin + AVD

From 2018 to 2022, industry-to-federally sponsored trial ratio was 8.1

Once-weekly efsitora noninferior to once-daily degludec for decrease in mean glycated hemoglobin level

Reductions seen in mean office sitting systolic BP and sitting diastolic BP and in mean 24-hour ambulatory systolic BP

Annualized rate of exacerbations reduced across two randomized trials in severe asthma with eosinophilic phenotype

Similar serious adverse event rate, clinical benefit seen for patients with versus those without a waiver

89 percent of cancer centers report that cancer drugs are in short supply, most often vinblastine, etoposide, and topotecan

In addition to enhanced performance, automated screening cuts costs

Survival benefits disappear when only high-quality studies are pooled and with adjustment for potential publication bias

Statistically significant survival gains observed for patients with solid tumors assigned to experimental group